Status: Documented pathogen in raw pet food surveillance; Campylobacter has higher source-ingredient prevalence than Salmonella in poultry-source products but produces different clinical disease patterns. Campylobacter jejuni and Campylobacter coli are Gram-negative microaerophilic bacterial pathogens that produce acute gastroenteritis in humans (diarrhea, abdominal pain, fever, sometimes bloody stool) and, in some cases, post-infection sequelae including reactive arthritis and Guillain-Barré syndrome (an autoimmune peripheral neuropathy). The pathogens are common contaminants on raw poultry with documented carriage rates of 30-80%+ in commercial broiler chicken populations at slaughter; the carriage rates are higher than Salmonella carriage rates in the same source population. Raw pet food Campylobacter prevalence reflects the source-ingredient pattern: commercial raw pet food using poultry source ingredients shows documented Campylobacter positivity at moderate-to-high rates in some surveillance studies, with rates varying widely across manufacturer and product category. The pathogen is less prominent in FDA-CVM enforcement than Salmonella partly because Campylobacter detection requires specific microaerophilic culture conditions that are not part of routine pathogen testing, and partly because the per-case human clinical severity (while real) is generally lower than the Salmonella or STEC per-case severity. The framework is documented in academic literature (veterinary and public health journals) and in some FDA-CVM surveillance reports but does not drive the same level of enforcement activity as Salmonella surveillance.

What was recalled

This page synthesizes the Campylobacter surveillance framework in commercial raw pet food. Campylobacter is a genus of Gram-negative, microaerophilic, spiral-shaped bacterial pathogens with multiple species; the two most-relevant species for foodborne disease are Campylobacter jejuni (the most-common Campylobacter species causing human disease) and Campylobacter coli (less common but clinically similar). The organisms have specific growth requirements (reduced oxygen tension, 42°C optimal temperature, complex nutritional requirements) that distinguish them from Salmonella and E. coli and require specialized culture methods for laboratory detection.

The source-ingredient prevalence pattern for Campylobacter is distinctive: commercial broiler chicken populations carry Campylobacter at rates of 30-80%+ in many studies and in some flocks essentially 100% of birds at slaughter test positive. Turkey, duck, and other poultry species carry Campylobacter at variable rates, generally lower than broiler chicken rates but still substantial. Cattle, sheep, and pigs carry Campylobacter at lower rates than poultry. The higher source-ingredient prevalence in poultry compared to other species translates to higher Campylobacter prevalence in poultry-based raw pet food.

The FDA-CVM surveillance treatment of Campylobacter is different from Salmonella. FDA-CVM routine surveillance sampling has historically focused more on Salmonella (which has standardized detection methods and well-established regulatory framework under FSMA Preventive Controls for Animal Food) than on Campylobacter (which has specialized detection methods and less well-established regulatory framework in pet food specifically). Academic literature on Campylobacter in raw pet food surveys is more substantial than FDA-CVM enforcement activity. The framework gap reflects the broader regulatory focus rather than the underlying public health significance.

Why it was recalled

The structural concerns have three layers. Layer one — Campylobacter is more prevalent than Salmonella in poultry source ingredients: source-ingredient carriage rates for Campylobacter in commercial poultry typically exceed Salmonella carriage rates by substantial margins. Raw pet food using poultry source ingredients would mathematically be expected to carry higher Campylobacter loading than Salmonella loading absent specific kill-step or QC intervention. The actual finished-product Campylobacter prevalence is moderated by Campylobacter’s lower environmental survival (it is more sensitive to oxygen, drying, and freezing than Salmonella) and lower thermal resistance, but the underlying source-ingredient pattern produces meaningful Campylobacter loading in raw poultry-based pet food.

Layer two — Campylobacter produces specific post-infection sequelae: beyond acute gastroenteritis, Campylobacter infection is associated with two specific post-infection sequelae of clinical significance. Reactive arthritis (also called Reiter’s syndrome) occurs in approximately 1-7% of Campylobacter infection cases, typically in genetically susceptible individuals (HLA-B27 positive), producing joint pain and inflammation weeks to months after the initial infection. Guillain-Barré syndrome (GBS), an autoimmune peripheral neuropathy producing ascending paralysis, occurs in approximately 1 per 1,000 Campylobacter infection cases — uncommon in absolute terms but accounting for approximately 30-40% of GBS cases in industrialized countries; GBS can be severe with substantial recovery time and some long-term sequelae. The post-infection sequelae elevate Campylobacter clinical significance beyond acute illness alone.

Layer three — Campylobacter detection requires specialized methods: microaerophilic culture conditions, specific media (Bolton broth, Campy-CCDA agar, others), and 42°C incubation distinguish Campylobacter detection from routine Salmonella/E. coli testing. Some QC programs include Campylobacter testing; many do not. Surveillance gaps reflect detection method specialization rather than absence of the pathogen. Manufacturer Campylobacter QC varies widely across the raw pet food industry.

Health risks for your pet

The health-risk pathway from Campylobacter in raw pet food parallels the Salmonella framework with distinctive disease pattern. Pet-direct risk is generally modest in adult dogs and cats — healthy adult pets are relatively resistant to Campylobacter clinical disease. Documented clinical campylobacteriosis in pets is most common in puppies and kittens, in immunocompromised pets, and in pets with concurrent gastrointestinal illness. Pets shed Campylobacter asymptomatically following exposure, supporting the zoonotic transmission pathway. Zoonotic-to-human risk includes acute gastroenteritis (diarrhea, abdominal pain, fever, sometimes bloody stool) as the typical presentation, plus the documented post-infection sequelae (reactive arthritis, Guillain-Barré syndrome) that distinguish Campylobacter from many other foodborne pathogens.

The vulnerable population framework includes the standard categories (immunocompromised, elderly, infants, pregnant women) plus HLA-B27 positive individuals (~5-10% of European-ancestry populations, lower in other ancestry groups) for reactive arthritis risk. The post-infection sequelae frame Campylobacter clinical significance beyond the immediate gastroenteritis episode and warrant inclusion in raw pet food handling guidance.

What to do if you bought affected product

Pet owners considering or feeding raw pet food, particularly poultry-based products, can take several practical approaches to manage Campylobacter risk: (1) recognize Campylobacter is a documented pathogen in raw pet food, particularly poultry-based products — the source-ingredient prevalence is higher than Salmonella in poultry; finished product prevalence is moderated by Campylobacter’s lower environmental survival but remains meaningful; (2) practice strict handling hygiene — the same practices that reduce Salmonella zoonotic risk apply to Campylobacter: thorough hand washing, sanitization of food preparation surfaces, separation of raw pet food handling from human food preparation; (3) select HPP-treated or kill-step-validated raw pet food — HPP achieves significant Campylobacter reduction (Campylobacter is more sensitive to HPP than Salmonella due to lower environmental hardiness); (4) consider acute gastroenteritis episodes with weeks-later joint pain as potentially Campylobacter — reactive arthritis can present weeks to months after the initial infection; HLA-B27 positive individuals have elevated risk; medical evaluation including history of Campylobacter exposure supports diagnosis; (5) recognize Guillain-Barré syndrome risk is low but real — approximately 1 per 1,000 Campylobacter infections progress to GBS; the absolute risk is low but the per-case clinical severity is high; acute progressive weakness or paralysis following a recent gastrointestinal illness warrants emergency medical evaluation; (6) consider non-poultry raw pet food categories for lower Campylobacter risk — beef, lamb, pork, and fish-based raw pet food typically carry lower Campylobacter risk than poultry-based products (though may carry other pathogen risks); (7) weigh Campylobacter framework alongside other raw pet food pathogen frameworks — the cumulative pathogen-load picture matters; Salmonella plus STEC plus Campylobacter plus Listeria together frame raw pet food handling risk.

How this affects KibbleIQ’s grade

The KibbleIQ rubric v15 evaluates raw pet food per our published methodology — Campylobacter surveillance status is considered indirectly through manufacturer QC factors. The framework is covered alongside parallel raw-feeding pathogen frameworks at our Salmonella raw pet food surveillance, E. coli STEC raw pet food, Listeria raw pet food controversy, raw pet food zoonotic transmission, and HPP validation controversy pages.